PubMed=15126569; DOI=10.1210/jc.2003-031314
Kaczirek K., Schindl M., Weinhausel A., Scheuba C., Passler C., Prager G., Raderer M., Hamilton G., Mittlbock M., Siegl V., Pfragner R., Niederle B.
Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines.
J. Clin. Endocrinol. Metab. 89:2397-2401(2004)

PubMed=17786610; DOI=10.1080/14653240701385836
Stadler G., Wieser M., Steindl F., Grillari J., Katinger H., Pfragner R., Voglauer R.
Development of standarDIzed cell culture conditions for tumor cells with potential clinical application.
Cytotherapy 9:488-498(2007)

PubMed=19424640; DOI=10.3892/or_00000391
Bachleitner-Hofmann T., Friedl J., Hassler M., Hayden H., Dubsky P., Sachet M., Rieder E., Pfragner R., Brostjan C., Riss S., Niederle B., Gnant M., Stift A.
Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.
Oncol. Rep. 21:1585-1592(2009)

PubMed=22038905; DOI=10.1002/ijc.26494
Flicker K., Ulz P., Hoger H., Zeitlhofer P., Haas O.A., Behmel A., Buchinger W., Scheuba C., Niederle B., Pfragner R., Speicher M.R.
High-resolution analysis of alterations in medullary thyroid carcinoma genomes.
Int. J. Cancer 131:E66-E73(2012)

CLPUB00412
Siddiqui Z.G.
Medullary thyroid cancer: the current state of tumour marker and treatment strategies.
Thesis MD (2015), Medical University of Graz, Austria